NRD
ADMA icon

Nebula Research & Development’s ADMA Biologics ADMA Stock Holding History

Nebula Research & Development’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,326
Closed -$79.9K – 624
2023
Q3 		$79.9K Buy
+22,326
New +$85.9K 0.04% 465

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nebula Research & Development's ADMA Position: Q4 2023 in Review

Nebula Research & Development sold out of ADMA Biologics (ADMA) in Q4 2023, closing a stake of 22,326 shares — an estimated $79.9K sold.

Nebula Research & Development first reported a position in ADMA in Q3 2023 and held it in 1 quarter. The position peaked at $79.9K in Q3 2023. 184 funds tracked by Wall St. Rank hold ADMA as of Q4 2023.

  • Nebula Research & Development reported no remaining ADMA Biologics position as of Q4 2023 after selling out during the quarter.
  • Nebula Research & Development sold 22,326 ADMA Biologics shares in Q4 2023, an estimated $79.9K.
  • Nebula Research & Development first reported a position in ADMA Biologics in Q3 2023 and held it in 1 quarter.
  • Nebula Research & Development's ADMA Biologics position peaked at $79.9K in Q3 2023.
  • 184 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2023.

Based on Nebula Research & Development's 13F filing for Q4 2023, filed 14 Feb 2024.